MX2008013760A - Compuestos restringidos como antagonistas del receptor del peptido relacionado con el gen de calcitonica (cgrp). - Google Patents

Compuestos restringidos como antagonistas del receptor del peptido relacionado con el gen de calcitonica (cgrp).

Info

Publication number
MX2008013760A
MX2008013760A MX2008013760A MX2008013760A MX2008013760A MX 2008013760 A MX2008013760 A MX 2008013760A MX 2008013760 A MX2008013760 A MX 2008013760A MX 2008013760 A MX2008013760 A MX 2008013760A MX 2008013760 A MX2008013760 A MX 2008013760A
Authority
MX
Mexico
Prior art keywords
oxo
mmol
mixture
chloro
indazol
Prior art date
Application number
MX2008013760A
Other languages
English (en)
Spanish (es)
Inventor
Haiquan Fang
Gene M Dubowchik
Xiaojun Han
Prasad V Chaturvedula
Guanglin Luo
Stephen E Mercer
Graham S Poindexter
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2008013760A publication Critical patent/MX2008013760A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2008013760A 2006-05-03 2007-05-02 Compuestos restringidos como antagonistas del receptor del peptido relacionado con el gen de calcitonica (cgrp). MX2008013760A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79740006P 2006-05-03 2006-05-03
US11/742,626 US7470680B2 (en) 2006-05-03 2007-05-01 Constrained compounds as CGRP-receptor antagonists
PCT/US2007/067998 WO2007131020A2 (en) 2006-05-03 2007-05-02 Constrained compounds as cgrp-receptor antagonists

Publications (1)

Publication Number Publication Date
MX2008013760A true MX2008013760A (es) 2008-11-14

Family

ID=38544174

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008013760A MX2008013760A (es) 2006-05-03 2007-05-02 Compuestos restringidos como antagonistas del receptor del peptido relacionado con el gen de calcitonica (cgrp).

Country Status (14)

Country Link
US (1) US7470680B2 (https=)
EP (1) EP2013214B1 (https=)
JP (1) JP2009535429A (https=)
KR (1) KR20090018930A (https=)
AR (1) AR060845A1 (https=)
AU (1) AU2007248038A1 (https=)
BR (1) BRPI0709759A2 (https=)
CA (1) CA2651033A1 (https=)
IL (1) IL195027A0 (https=)
MX (1) MX2008013760A (https=)
NO (1) NO20084564L (https=)
PE (1) PE20080232A1 (https=)
TW (1) TW200813063A (https=)
WO (1) WO2007131020A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
EP2120564A4 (en) * 2006-12-20 2011-05-04 Merck Sharp & Dohme BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS
JP2011512410A (ja) * 2008-02-19 2011-04-21 メルク・シャープ・エンド・ドーム・コーポレイション イミダゾベンゾアゼピンcgrp受容体アンタゴニスト
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
WO2024220626A1 (en) * 2023-04-20 2024-10-24 Azkarra Therapeutics, Inc. Small molecule modulators of ogg1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205293B2 (en) 2003-03-14 2007-04-17 Merck & Co., Inc. Benodiazepine spirohydantoin CGRP receptor antagonists
CA2518830A1 (en) 2003-03-14 2004-09-30 Merck & Co., Inc. Carboxamide spirohydantoin cgrp receptor antagonists
JP4705908B2 (ja) * 2003-04-15 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Cgrp受容体拮抗薬
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2005000807A2 (en) 2003-06-26 2005-01-06 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
CA2529196A1 (en) 2003-06-26 2005-02-17 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
JP4705922B2 (ja) 2004-01-29 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Cgrp受容体拮抗薬
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
CA2582593A1 (en) 2004-10-07 2006-04-20 Merck & Co., Inc. Cgrp receptor antagonists
BRPI0517418A (pt) 2004-10-13 2008-10-07 Merck & Co Inc composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça
AU2005295855B2 (en) 2004-10-14 2011-08-18 Merck Sharp & Dohme Corp. CGRP receptor antagonists
AU2005299852B2 (en) 2004-10-22 2011-08-04 Merck Sharp & Dohme Corp. CGRP receptor antagonists
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
CA2594940A1 (en) 2005-01-18 2006-07-27 Merck & Co., Inc. Cgrp receptor antagonists
CN101208303A (zh) 2005-03-14 2008-06-25 默克公司 Cgrp受体拮抗剂
WO2007016087A2 (en) 2005-07-29 2007-02-08 Merck & Co., Inc. Heterocyclic benzodiazepine cgrp receptor antagonists
EP2120564A4 (en) 2006-12-20 2011-05-04 Merck Sharp & Dohme BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
KR20090018930A (ko) 2009-02-24
WO2007131020A2 (en) 2007-11-15
US7470680B2 (en) 2008-12-30
CA2651033A1 (en) 2007-11-15
EP2013214A2 (en) 2009-01-14
JP2009535429A (ja) 2009-10-01
AR060845A1 (es) 2008-07-16
TW200813063A (en) 2008-03-16
AU2007248038A1 (en) 2007-11-15
WO2007131020A3 (en) 2008-01-17
BRPI0709759A2 (pt) 2011-10-25
US20070259851A1 (en) 2007-11-08
PE20080232A1 (es) 2008-04-11
IL195027A0 (en) 2009-08-03
NO20084564L (no) 2008-12-02
EP2013214B1 (en) 2015-06-24

Similar Documents

Publication Publication Date Title
US7544680B2 (en) Constrained compounds as CGRP-receptor antagonists
JP6258537B2 (ja) Cgrp受容体アンタゴニスト
EP1945222B1 (en) Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
WO2007130860A2 (en) Constrained compounds as cgrp-receptor antagonists
CA2583536A1 (en) Cgrp receptor antagonists
EP3480198A1 (en) Novel compound or pharmaceutically acceptable salt thereof
WO2012022707A1 (en) Substituted heteroaryl spiropyrrolidine mdm2 antagonists
AU2007314338A1 (en) Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease
EP2013214B1 (en) Constrained compounds as cgrp-receptor antagonists
CN101495480B (zh) 作为降钙素基因相关肽受体拮抗剂的受限化合物
EP2013213B1 (en) Constrained compounds as cgrp-receptor antagonists
US20090054440A1 (en) Quinoline derivatives as neurokinin receptor antagonists
CN101094854A (zh) 作为cgrp受体拮抗剂的受限化合物

Legal Events

Date Code Title Description
FA Abandonment or withdrawal